Neurology Medical News about Lacosamide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety
Therapeutics and Clinical Risk Management, 09/24/09

Kellinghaus C – LCM is approved for treatment of partial seizures with or without secondary generalization in the United States and the European Union within a dose range of 200 to 400 mg per day, administered twice daily. In addition to the oral formulations, an intravenous infusion solution is available.

<< Previous
Multiple Sclerosis With Predominant, Severe Cognitive Impairment

Next >>
Current Alzheimer's disease clinical trials: Methods and placebo...

Lacosamide: An Adjunctive Agent for Partial-Onset Seizures and Potential Therapy for Neuropathic Pain
Annals of Pharmacotherapy, 10/22/09 Relevance Score: 80%